Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease

被引:50
作者
Hurley, MJ
Mash, DC
Jenner, P
机构
[1] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA
[2] Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Neurodegenerat Dis Res Ctr, London SE1 1UL, England
来源
MOLECULAR BRAIN RESEARCH | 2001年 / 87卷 / 02期
关键词
basal ganglia; dopamine D-1 receptor; Parkinson's disease; radioligand binding; RT-PCR;
D O I
10.1016/S0169-328X(01)00022-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The expression of the human dopamine D-1 receptor was examined by reverse transcription polymerase chain reaction (RT-PCR) and radioligand binding using [H-3]-SCH23390 in post-mortem brain tissue that was obtained from normal subjects and patients dying with Parkinson's disease who were receiving treatment with dopaminergic drugs. D-1 receptor mRNA and specific [H-3]-SCH23390 binding sites were found in both striatal (nucleus accumbens, caudate nucleus and putamen) and extrastriatal (globus pallidus and substantia nigra) brain regions. In parkinsonian brain, D-1 receptor mRNA was increased in the nucleus accumbens, while a decrease was detected in the substantia nigra pars compacta. No change in D-1 mRNA levels was found in the other brain areas examined. An increase in the density of specific [H-3]-SCH23390 binding sites was found in the anterior putamen and a decrease in the external segment of the globus pallidus, no changes were detected elsewhere. This study demonstrates that regulation of D-1 receptor expression in the brain of patients dying with Parkinson's disease that were treated with L-DOPA is confined to small alterations in restricted brain regions. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:271 / 279
页数:9
相关论文
共 63 条
[1]  
ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
[2]  
Asin KE, 1997, J PHARMACOL EXP THER, V281, P454
[3]  
Bj?rklund A., 1984, HDB CHEM NEUROANAT 1, P55
[4]  
BLANCHET P, 1993, J PHARMACOL EXP THER, V267, P275
[5]   IS STRIATAL DOPAMINERGIC RECEPTOR IMBALANCE RESPONSIBLE FOR LEVODOPA-INDUCED DYSKINESIA [J].
BLANCHET, PJ ;
GOMEZMANCILLA, B ;
DIPAOLO, T ;
BEDARD, PJ .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1995, 9 (05) :434-442
[6]   [H-3] SPIPERONE BINDING, DOPAMINE AND HVA CONCENTRATIONS IN PARKINSONS-DISEASE AND SUPRANUCLEAR PALSY [J].
BOKOBZA, B ;
RUBERG, M ;
SCATTON, B ;
JAVOYAGID, F ;
AGID, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 99 (2-3) :167-175
[7]   SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE [J].
BRAUN, A ;
FABBRINI, G ;
MOURADIAN, MM ;
SERRATI, C ;
BARONE, P ;
CHASE, TN .
JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (1-2) :41-50
[8]   What do the basal ganglia do? [J].
Brown, P ;
Marsden, CD .
LANCET, 1998, 351 (9118) :1801-1804
[9]   DOPAMINE D-1 RECEPTOR AND CYCLIC AMP-DEPENDENT PHOSPHORYLATION IN PARKINSONS-DISEASE [J].
CASH, R ;
RAISMAN, R ;
PLOSKA, A ;
AGID, Y .
JOURNAL OF NEUROCHEMISTRY, 1987, 49 (04) :1075-1083
[10]   FAILURE OF SKF 38393-A TO RELIEVE PARKINSONIAN SYMPTOMS INDUCED BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE IN THE MARMOSET [J].
CLOSE, SP ;
MARRIOTT, AS ;
PAY, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1985, 85 (02) :320-322